APA-referens

Tsai, J. N., Lee, H., David, N. L., Eastell, R., & Leder, B. Z. (2019). Combination denosumab and high dose teriparatide for postmenopausal osteoporosis (DATA-HD): A randomised, controlled phase 4 trial. Lancet Diabetes Endocrinol.

Chicago-stil citat

Tsai, Joy N., Hang Lee, Natalie L. David, Richard Eastell, och Benjamin Z. Leder. "Combination Denosumab and High Dose Teriparatide for Postmenopausal Osteoporosis (DATA-HD): A Randomised, Controlled Phase 4 Trial." Lancet Diabetes Endocrinol 2019.

MLA-referens

Tsai, Joy N., et al. "Combination Denosumab and High Dose Teriparatide for Postmenopausal Osteoporosis (DATA-HD): A Randomised, Controlled Phase 4 Trial." Lancet Diabetes Endocrinol 2019.

Varning: dessa hänvisningar är inte alltid fullständigt riktiga.